Discover how Ultragenyx achieved 29% revenue growth in 2024, set 2025 guidance at $640M-$670M, and advanced clinical progress toward profitability by 2027.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Leveraging a partner with domain expertise in pharma and experience in AI and GenAI is essential for transitioning from data to actionable insights. Let’s start with the basics: How does GenAI ...

According to GlobalData, Qulipta has the edge when it comes to data on migraine prevention ... After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk ...

Timeseries are determined for each Australian State, the Northern Territory and the six regions shown above The actual data values used to produce each graph are available via the "Raw dataset" link.